CORDIS
EU research results

CORDIS

English EN
Professional cross-priming for ovary and prostate cancer

Professional cross-priming for ovary and prostate cancer

Objective

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

Coordinator

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Address

Avenida De Pio Xii 55
31008 Pamplona

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 190 000

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 1 510 000

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 1 345 000

CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)

Spain

EU Contribution

€ 655 000

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 1 050 000

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

UNIVERSITE DE LAUSANNE

Switzerland

Project information

Grant agreement ID: 635122

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 7 572 500

  • EU contribution

    € 5 750 000

Coordinated by:

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Spain